BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gocatamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gocatamig\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04471727-11236@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Gocatamig: Phase 1/2 readout est. (NCT04471727)
DESCRIPTION:Gocatamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Study
  in Participants With Advanced Cancers Associated With Expression of DLL3 
 (MK-6070-001/HPN328-4001)\nEstimated primary completion: 28 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/gocatamig#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04471727
URL:https://assetmemo.bio/drug/gocatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780137-11236@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Gocatamig: Phase 1/2 readout est. (NCT06780137)
DESCRIPTION:Gocatamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Study
  to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab
  Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Sta
 ge Small Cell Lung Cancer (MK-6070-002)\nEstimated primary completion: 15 
 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gocata
 mig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06780137
URL:https://assetmemo.bio/drug/gocatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227597-11236@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20301129
DTEND;VALUE=DATE:20301130
SUMMARY:Gocatamig: Phase 1/2 readout est. (NCT07227597)
DESCRIPTION:Gocatamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Clini
 cal Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in P
 eople With Small Cell Lung Cancer (MK-6070-003)\nEstimated primary complet
 ion: 29 November 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/gocatamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07227597
URL:https://assetmemo.bio/drug/gocatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908537-11236@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20311208
DTEND;VALUE=DATE:20311209
SUMMARY:Gocatamig: Phase 3 readout est. (NCT07908537)
DESCRIPTION:Gocatamig\, phase 3\, Small Cell Lung Cancer.\nStudy: A Clinica
 l Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small 
 Cell Lung Cancer (MK-6070-004)\nEstimated primary completion: 8 December 2
 031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/gocatamig#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07908537
URL:https://assetmemo.bio/drug/gocatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
